Stockwatch: Pfizer, Roche, AZ, Novo Prolong Pharmaceutical Winter
Executive Summary
Lackluster reports from Pfizer, Roche, AstraZeneca and Novo Nordisk in a second week of earnings season pervaded by below consensus 2017 guidance followed a first week punctuated by missed sales estimates. So much bad news hanging over the sector feels like a nuclear winter.
You may also be interested in...
Carrots and Stick: Biopharma At The White House
Drug industry executives discuss drug pricing and tax and regulatory reform in a high-profile meeting with President Trump at the White House.
Pfizer Not Making Pricing Changes, Sees Ways To Work With Trump
Pfizer CEO Ian Read said during the company’s quarterly call that there are ‘lots of ways’ to work with the new Trump administration, his comments coming on the same day several industry leaders met with the new US president.
Novo Nordisk Shakes Up R&D Strategy To Cope With US Pricing Pressures
Increasing competition and pricing pressures in the US, have led Novo Nordisk to halve its profit growth expectations for 2017. In response, the diabetes drug developer plans to double-down on R&D efforts, expand into new therapy areas and seek external deals for early-stage assets to bulk up its pipeline.